N/A N=10 Renal Retention of Microbubbles
- Study Focus: Renal Retention of Lipid Microbubbles
Primary: Renal Video Intensity Units — 19 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?
Transplantation, Kidney
Primary: Abnormal Biopsy — 10; 7 Participants
Phase 2 N=10 Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
Urinary Tract Infection · Vesicoureteral Reflux
Primary: Visualization of Renal Scars Compared to Previous Imaging — 100 Percentage of previous scars visualized
N/A N=11 Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Kidney Cancer
Primary: Successful Capture of IO-CEUS Images — 10 participants
N/A N=103 Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
Chronic Kidney Disease · Cardiovascular Disease
Primary: In Vitro Lipoprotein Functions — 20.8; 26.5 Percentage of cholesterol content
N/A N=15 Evaluation of Lipid Emulsion on GCX in Critically Ill Patients
Endothelial Dysfunction
Primary: Endothelial Glycocalyx Thickness — 2.28 micrometer
N/A N=92 Long-Term Retention of Gadolinium in Bone
Focus: Long-term Retention of Gadolinium-based Contrast Agent
Primary: Concentration of Total Gadolinium in Trabecular Bone — 0.335; 0.783; 0; 0 micrograms/gram
Phase 4 N=132 Renal Safety Evaluation After Dotarem®-Enhanced MRI
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
Phase 2 N=36 A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
Cardiac Disease
Primary: 12-lead ECGs — 393.9; 392.0; 386.3; 2.8 millisecond
Phase 2 N=104 Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
Hepatocellular Carcinoma
Primary: Treatment Response to Yttrium Y-90 Radioembolization — 2; 17; 17; 17 Participants
Phase 4 N=21 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI — 22.04 1/ms
N/A N=8 Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Liver Neoplasms
Primary: Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography — 8 tumor
Phase 2 N=53 Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Renal Cell Carcinoma
Primary: The Sensitivity of Detecting RCC Recurrence (Using Contrast-enhanced MRI as a Reference Standard) on a Single Contrast-enhanced Ultrasound Exam. — 100 percent of patients
Phase 2 N=63 Contrast-enhanced Ultrasound of the Kidney
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
Phase 2 N=22 Lipid Infusion in Dialysis Patients With Endotoxemia
Fatigue · End Stage Renal Disease (ESRD)
Primary: Reduction in Endotoxin Levels. — 5; 5 Participants
Phase 3 N=174 Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Coronary Artery Disease
Primary: Sensitivity and Specificity of Lumason Enhanced Dobutamine Stress Echo (DSE) for Detection or Exclusion of Coronary Artery Disease (CAD) — 16.0; 37.9 percentage of…
Phase 3 N=175 Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Coronary Artery Disease
Primary: Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD) — 8.0; 33.7 percentage of participants — p=0.0896
N/A N=8 Acute Microvascular Changes With LDL Apheresis
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
Phase 3 N=315 Gadobutrol Enhanced MRA of the Renal Arteries
Renal Artery Obstruction
Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.9; 77.6; 98.1; 81.7 Percentage of segments — p=<0.000
Phase 2 N=25 Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Chronic Kidney Diseases · Cystic Kidney Disease
Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants
Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
N/A N=30 LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound
Dehydration in Children · Dehydration
Primary: Duration- Ultrasound Ordered to Completed — 154.4; 114.8 minutes
N/A N=28 Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
N/A N=21 Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
Renal Transplant Rejection
Primary: Radiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* Maps — 31.1; 23.3 ms (delayed postcontrast scans)
N/A N=13 Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Obesity-induced Hyperfiltration
Primary: Change in GFR (ml/Min) — 151; 152; 120; 150 ml/min
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Phase 4 N=357 Primovist / Eovist in Renally Impaired Patients
Contrast Media
Primary: Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and…
Phase 2 N=234 Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Acute Kidney Injury
Primary: Number of Participants With Treatment-Emergent Adverse Events — 7; 7; 2; 1 Participants
Phase 2 N=237 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
Hyperlipidemia
Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] — 0.938; 1.082; 0.759 ratio